Kisspeptin 10

Kisspeptin-10 functions as a potent stimulator of gonadotropin release, particularly luteinizing hormone (LH) and follicle-stimulating hormone (FSH), making it therapeutically relevant for reproductive disorders characterized by dysfunctional gonadotropin signaling¹. Clinical research has demonstrated that intravenous kisspeptin-10 administration rapidly increases LH secretion in men, with continuous infusion sustaining elevated LH levels and increasing testosterone production². The primary therapeutic applications under investigation include treatment of hypothalamic amenorrhea and polycystic ovary syndrome (PCOS), where kisspeptin-10 addresses underlying hormonal dysregulation by restoring synchronized gonadotropin response¹. Emerging evidence from animal studies and early human research suggests potential utility in managing low libido and sexual dysfunction in both men and women by targeting the hypothalamic mechanisms regulating sexual desire rather than addressing symptoms alone³,⁴,⁵. Additionally, kisspeptin analogs are being explored for their potential role in suppressing sex hormone signaling relevant to hormone-sensitive malignancies such as prostate and breast cancer, representing a distinct therapeutic avenue from the gonadotropin-stimulating properties of kisspeptin-10 itself³.

Kisspeptin-10 side effects are generally mild and transient, commonly including nausea, vomiting, diarrhea, headache, increased sweating, hot flashes, postural dizziness, flushing, mild injection site reactions such as redness, swelling, or pain, and rare appetite suppression with reduced food intake.⁶,⁷,⁸ These effects often subside after initial doses as the body adjusts, with serious adverse events being rare and no significant impacts on blood pressure, heart rate, or mood reported in clinical studies.⁷,⁹,¹⁰ Safety considerations include using it only under medical supervision, adhering strictly to prescribed dosages to avoid exceeding limits or frequent changes, and consulting a physician if symptoms persist, worsen, or include hormonal fluctuations.⁴,⁶,⁷ High-dose or chronic administration in preclinical models has shown risks like tachyphylaxis or testicular degeneration, underscoring the need for monitored use in humans.¹¹ Overall, Kisspeptin-10 exhibits a favorable safety profile when administered as directed in research settings.⁶,⁷,⁹

Kisspeptin-10 operates as a neuropeptide ligand that binds to the GPR54 receptor, also known as KISS1R, which is essential for reproductive hormone physiology¹²,¹³. Upon receptor activation, kisspeptin-10 triggers a cascade of intracellular signaling through phospholipase C and G-protein coupling, leading to calcium mobilization and depolarization of neurons¹³,¹⁴. This activation stimulates the release of gonadotropin-releasing hormone (GnRH) from hypothalamic neurons, with studies indicating the peptide can stimulate over 85% of GnRH neurons¹². The GnRH subsequently drives the pulsatile secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland; at lower concentrations kisspeptin-10 enhances the frequency of LH pulses, while higher concentrations can produce continuous LH release¹²,¹⁵. Beyond reproductive signaling, research suggests kisspeptin-10 may modulate mood and behavior, facilitate angiogenesis, and exert neuroprotective effects against amyloid-related neurotoxicity¹²,¹⁶.